MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Minerva Neurosciences Inc

Cerrado

1.58 3.27

Resumen

Variación precio

24h

Actual

Mínimo

1.48

Máximo

1.78

Métricas clave

By Trading Economics

P/B

Media del Sector

8.167

63.778

Empleados

8

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+222.58% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-1.9M

11M

Apertura anterior

-1.69

Cierre anterior

1.58

Minerva Neurosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 23:55 UTC

Acciones populares

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 abr 2025, 22:50 UTC

Principales Movimientos del Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 abr 2025, 21:08 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 abr 2025, 21:00 UTC

Ganancias

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 abr 2025, 23:56 UTC

Charlas de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 abr 2025, 23:44 UTC

Principales Noticias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 abr 2025, 23:32 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 23:32 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 23:32 UTC

Charlas de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 abr 2025, 23:12 UTC

Charlas de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 abr 2025, 23:10 UTC

Charlas de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 abr 2025, 23:09 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:57 UTC

Charlas de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 abr 2025, 22:56 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 22:56 UTC

Charlas de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 abr 2025, 22:43 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 abr 2025, 22:12 UTC

Charlas de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 abr 2025, 21:48 UTC

Principales Noticias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 abr 2025, 21:41 UTC

Charlas de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 abr 2025, 21:17 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 abr 2025, 21:17 UTC

Charlas de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 abr 2025, 21:04 UTC

Principales Noticias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 abr 2025, 21:03 UTC

Charlas de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 abr 2025, 20:53 UTC

Ganancias

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 abr 2025, 20:52 UTC

Ganancias

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparación entre iguales

Cambio de precio

Minerva Neurosciences Inc previsión

Precio Objetivo

By TipRanks

222.58% repunte

Estimación a 12 Meses

Media 5 USD  222.58%

Máximo 5 USD

Mínimo 5 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Minerva Neurosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Finanzas

$

Acerca de Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.